SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

13 Aug 2022 Evaluate
The revenue for the June 2022 quarter is pegged at Rs. 1591.52 millions, about 8.10% up against Rs. 1472.21 millions recorded during the year-ago period.A big decline of -33.56% was reported for the quarter ended June 2022 to Rs. 192.06  millions from Rs. 289.06 millions of corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 310.39 millions from 390.37 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1591.52 1472.21 8.10 1591.52 1472.21 8.10 6582.89 5995.48 9.80
Other Income 194.32 139.40 39.40 194.32 139.40 39.40 422.51 311.56 35.61
PBIDT 310.39 390.37 -20.49 310.39 390.37 -20.49 1559.66 1448.68 7.66
Interest 8.17 6.30 29.68 8.17 6.30 29.68 37.95 53.45 -29.00
PBDT 302.22 384.07 -21.31 302.22 384.07 -21.31 1521.71 1395.23 9.07
Depreciation 45.18 42.29 6.83 45.18 42.29 6.83 176.63 151.93 16.26
PBT 257.04 341.78 -24.79 257.04 341.78 -24.79 1345.08 1243.30 8.19
TAX 64.98 52.72 23.25 64.98 52.72 23.25 305.20 259.49 17.62
Deferred Tax -0.94 -3.52 -73.30 -0.94 -3.52 -73.30 5.04 -22.39 -122.51
PAT 192.06 289.06 -33.56 192.06 289.06 -33.56 1039.88 983.81 5.70
Equity 409.31 409.31 0.00 409.31 409.31 0.00 409.31 409.31 0.00
PBIDTM(%) 19.50 26.52 -26.45 19.50 26.52 -26.45 23.69 24.16 -1.95

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×